PHARMA MAR, S.A. «12345...» Page 2 out of 10 from 01/07/1988 to 22/03/2018 The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish 15/12/2017 12:43 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks In relation to the Significant Fact n. 258359, the CHMP of EMA has finally emitted its opinion against the approval of Aplidin® in multiple myeloma. Register number: 259611 11/12/2017 08:18 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks In relation to Significant Fact n 236.798, presentation of results from ADMYRE Phase III trial of plitidepsin in multiple myeloma at the 59th American Society of Hematology annual Meeting & Exposition. Register number: 259246 15/11/2017 08:12 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks After analysis of the safety data of the first 150 patients, IDMC recommends that the Phase III trial with Zepsyre® in small-cell lung cancer patients should continue without any changes Register number: 258531 14/11/2017 08:09 PHARMA MAR, S.A. Announcements of public presentations and meetings Pharma Mar will participate in the Stifel Nicolaus Weisel Healthcare Conference to be held in New York on Nov. 15. Register number: 258469 08/11/2017 19:31 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks Pharma Mar announces CHMP negative trend vote in relation to Aplidin Marketing Authorization Application for multiple myeloma. Register number: 258359 24/10/2017 17:49 PHARMA MAR, S.A. Information on P&L The Company sends press release regarding the third quarter 2017 results. Register number: 257730 24/10/2017 17:42 PHARMA MAR, S.A. Interim financial information La sociedad remite información sobre los resultados del tercer trimestre de 2017 Register number: 257728 11/10/2017 17:42 PHARMA MAR, S.A. Liquidity contracts and specialists The Company reports details of the operations of the Liquidity Agreement between 11/07/2017 and 10/10/2017 Register number: 257312 28/09/2017 18:18 PHARMA MAR, S.A. Liquidity contracts and specialists The Company reports on the adjustments of the balances in the securities and cash account associated with the liquidity agreement entered into with the entity Mediación Bursátil, Sociedad de Valores, S.A. Register number: 256845 19/09/2017 16:30 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks Press release announcing the start of clinical development with a Pharma Mar´s new antitumor compound Register number: 256535 Page 2 out of 10 «12345...»